Kymera Therapeutics Announces Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the Society for Investigative Dermatology and American Thoracic Society Congresses
Go back to Kymera Therapeutics Announces Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the Society for Investigative Dermatology and American Thoracic Society Congresses| (NASDAQ: KYMR) | Delayed: 90.43 +0.53 (0.59%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $89.90 | 52 Week High | $ | |||
| Open | $90.68 | 52 Week Low | $ | |||
| Day High | $92.47 | P/E | N/A | |||
| Day Low | $89.18 | EPS | $ | |||
| Volume | 1,262,295 | |||||
